Provided by Tiger Trade Technology Pte. Ltd.

Pacira Pharmaceuticals

25.05
-0.1600-0.63%
Volume:560.25K
Turnover:14.08M
Market Cap:998.54M
PE:71.21
High:25.71
Open:25.37
Low:24.83
Close:25.21
52wk High:27.66
52wk Low:18.80
Shares:39.86M
Float Shares:36.37M
Volume Ratio:1.02
T/O Rate:1.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3518
EPS(LYR):0.1578
ROE:2.05%
ROA:1.48%
PB:1.49
PE(LYR):158.71

Loading ...

Stock Track | Pacira Pharmaceuticals Plummets 5.57% Intraday After Q1 Earnings Decline and Maintained Forecast

Stock Track
·
May 01

Analysts’ Top Healthcare Picks: Pacira Pharmaceuticals (PCRX), Cadrenal Therapeutics, Inc. (CVKD)

TIPRANKS
·
May 01

RBC Raises Price Target on Pacira Biosciences to $24 From $22, Keeps Sector Perform Rating

MT Newswires Live
·
May 01

Stock Track | Pacira Pharmaceuticals Soars 5.41% Intraday on Strong Q1 Earnings Beat, Revenue Growth and Maintained Buy Rating

Stock Track
·
May 01

Stock Track | Pacira Pharmaceuticals Soars 5.10% in Pre-Market on Strong Q1 Results and Maintained Buy Rating

Stock Track
·
May 01

Pacira BioSciences Is Maintained at Buy by Needham

Dow Jones
·
May 01

Pacira Q1 revenue beats estimates, co raises 2026 outlook

Reuters
·
May 01

Pacira reports Q1 EPS 60c, consensus 56c

TIPRANKS
·
May 01

Pacira Q1 FY26 net income drops 39% to USD 2.9 million; revenue rises 5% to USD 177 million

Reuters
·
May 01

BRIEF-Pacira Biosciences Q1 Revenue USD 177 Million Vs. IBES Estimate USD 173.3 Million

Reuters
·
May 01

Pacira BioSciences Q1 Adj. EPS $0.60 Beats $0.56 Estimate, Sales $177.376M Beat $173.325M Estimate

Benzinga Earnings
·
May 01

Pacira Biosciences Inc - Reiterates 2026 Guidance

THOMSON REUTERS
·
May 01

Pacira Biosciences Q1 Cash & Investments USD 202.2 Million

THOMSON REUTERS
·
May 01

Pacira urges vote for board slate as activist DOMA pushes company sale at June 9 meeting

Reuters
·
Apr 29

Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty

GlobeNewswire
·
Apr 27

Pacira CFO Shawn Cross disposes of 12,941 common shares for $325,597.56

Reuters
·
Apr 25

Earning Preview: Pacira Pharmaceuticals this quarter’s revenue is expected to decrease by 1.35%, and institutional views are bullish

Earnings Agent
·
Apr 24

Pacira CFO Shawn Cross disposes 12,059 common shares for $303,299.99

Reuters
·
Apr 23

A Look At Pacira BioSciences (PCRX) Valuation After New EXPAREL Health Economic Data

Simply Wall St.
·
Apr 21

H.C. Wainwright Reaffirms Their Buy Rating on Pacira Pharmaceuticals (PCRX)

TIPRANKS
·
Apr 20